Martín-Aguilar, LorenaCamps-Renom, PolLleixà, CintaPascual-Goñi, ElbaDíaz-Manera, JordiRojas-García, RicardoDe Luna, NoemiGallardo, EduardCortés-Vicente, ElenaMuñoz, LaiaAlcolea, DanielLleó, AlbertoCasasnovas, CarlosHomedes, ChristianGutiérrez-Gutiérrez, GerardoJimeno-Montero, María ConcepciónBerciano, JoséSedano-Tous, María JoséGarcía-Sobrino, TaniaPardo-Fernández, JulioMárquez-Infante, CeledonioRojas-Marcos, IñigoJericó-Pascual, IvonneMartínez-Hernández, EugeniaMorís de la Tassa, GermánDomínguez-González, CristinaIlla, IsabelQuerol, Luis2023-02-092023-02-092020-11-05http://hdl.handle.net/10668/16560To study baseline serum neurofilament light chain (sNfL) levels as a prognostic biomarker in Guillain-Barré syndrome (GBS). We measured NfL in serum (98 samples) and cerebrospinal fluid (CSF) (24 samples) of patients with GBS prospectively included in the International GBS Outcome Study (IGOS) in Spain using single-molecule array (SiMoA) and compared them with 53 healthy controls (HCs). We performed multivariable regression to analyse the association between sNfL levels and functional outcome at 1 year. Patients with GBS had higher NfL levels than HC in serum (55.49 pg/mL vs 9.83 pg/mL, p319 pg/mL), inability to run (>248 pg/mL) and ability to run (248 pg/mL) and ability to run ( Baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/research article33154183open access10.1136/jnnp-2020-3238991468-330Xhttps://www.medrxiv.org/content/medrxiv/early/2020/03/30/2020.03.24.20042200.full.pdf